SkinBioTherapeutics Net Income From Continuing Ops from 2010 to 2024
| SBTX Stock | 15.88 0.12 0.75% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -2.6 M | Current Value -2.4 M | Quarterly Volatility 1.1 M |
Check SkinBioTherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among SkinBioTherapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 37.8 K, Interest Expense of 10.7 K or Selling General Administrative of 2.5 M, as well as many indicators such as . SkinBioTherapeutics financial statements analysis is a perfect complement when working with SkinBioTherapeutics Valuation or Volatility modules.
SkinBioTherapeutics | Net Income From Continuing Ops |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for SkinBioTherapeutics Stock Analysis
When running SkinBioTherapeutics' price analysis, check to measure SkinBioTherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SkinBioTherapeutics is operating at the current time. Most of SkinBioTherapeutics' value examination focuses on studying past and present price action to predict the probability of SkinBioTherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SkinBioTherapeutics' price. Additionally, you may evaluate how the addition of SkinBioTherapeutics to your portfolios can decrease your overall portfolio volatility.